Maze Therapeutics Inc 2024年度报告

(Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period from __________ to __________Commission File Number: 001-42490 MAZE THERAPEUTICS, INC. 82-2635018(I.R.S. Employer Identification No.) Delaware (State or other jurisdiction of incorporation or organization) 171 Oyster Point Blvd., Suite 300South San Francisco, California 94080(Address of principal executive offices, including zip code)(650) 850-5070(Registrant's telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registered Securities registered pursuant to Section 12(g) of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES☐NO☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES☐NO☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES☐NO☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 ofthis chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES☐NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reportingunder Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’sexecutive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES☐NO☒ The registrant did not have a public float on the last business day of its most recently completed second fiscal quarter because there was no public market for the registrant’s commonAs of March 25, 2025, the registrant had 43,796,057 shares of common stock outstanding. PageNumbers PART I4Item 1.Business4Item 1A.Risk Factors42Item 1B.Unresolved Staff Comments93Item 1C.Cybersecurity93Item 2.Properties94Item 3.Legal Proceedings94Item 4.Mine Safety Disclosures94PART II95Item 5.Market for Registrant's Common Equity, Related Stockholder Matters, and IssuerPurchases of Equity Securities95Item 6.[Reserved]96Item 7.Management's Discussion and Analysis of Financial Condition and Results ofOperations97Item 7A.Quantitative and Qualitative Disclosures About Market Risk109Item 8.Financial Statements and Supplementary Data110Item 9.Changes in and Disagreements with Accountants on Accounting and FinancialDisclosure139Item 9A.Controls and Procedures139Item 9B.Other Information139Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections139PART III140Item 10.Directors, Executive Officers and Corporate Governance140Item 11.Executive Compensation148Item 12.Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters162Item 13.Certain Relationships and Related Transactions, and Director Independence166Item 14.Principal Accountant Fees and Services168PART IV169Item 15.Exhibits and Financial Statement Schedules169Item 16.Form 10-K Summary171SIGNATURE PAGE172 Special note regarding forward-looking state